Changes in Hong Kong stocks | Keji Pharmaceutical-B (02171) rose nearly 5% in early trading, Hong Kong's business made significant progress and further promoted Kailimei's international layout

The Zhitong Finance App learned that Keji Pharmaceutical-B (02171) rose nearly 5% in early trading. As of press release, it rose 3.61% to HK$12.92, with a turnover of HK$17.974 million.

According to the news, Keji Pharmaceutical announced that the company has made significant progress in its business related to advanced therapy products in Hong Kong and has obtained the necessary licensing qualifications to carry out the wholesale supply business of related pharmaceutical products. The acquisition of this license is an important milestone in Keji Pharmaceutical's promotion of the international layout of Kalimei (Shuriki Orense Injection). It has laid the foundation for the company to further explore Kailimei's patient accessibility pathways and related business development in Hong Kong, and has also accumulated important experience for the company to continue to expand overseas markets.

In the future, Keji Pharmaceutical will continue to promote Kailimei's global layout, actively explore overseas market access and patient accessibility routes, including Hong Kong, and strengthen collaboration with local medical institutions and partners to make innovative cell therapies benefit more patients around the world.